Physician profile
Tanya Devnani
NPI 1265846554
$3,160.91
in general payments reported to CMS, 2019-2025
25 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 80% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.71 · 2020: $12.12 · 2021: $80.67 · 2022: $245 · 2023: $922 · 2024: $659 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,752.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $600.21 | 2022-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $326.54 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.76 | 2022-2025 | Ofev, Stiolto Respimat |
| Grifols USA, LLC | $206.86 | 2019-2025 | Prolastin-C Liquid |
| Pfizer INC. | $200.81 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $188.74 | 2022-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $183.27 | 2023-2025 | Dupixent |
| Amgen INC. | $144.63 | 2023-2025 | Tezspire |
| Genzyme Corporation | $139.40 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $119.07 | 2022-2023 | Xarelto |
| Mallinckrodt Hospital Products INC. | $105.63 | 2022-2024 | Acthar |
| Boston Scientific Corporation | $96.16 | 2021-2023 | Exalt Model D |
| Actelion Pharmaceuticals US, INC. | $93.66 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Verona Pharma, INC. | $87.75 | 2025 | Ohtuvayre |
| Abbvie INC. | $83.70 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $60.91 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Inogen, INC. | $47.37 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Gilead Sciences, INC. | $46.18 | 2024 | |
| Viatris Specialty LLC | $33.58 | 2025 | Yupelri |
| Mylan Specialty L.P. | $28.73 | 2022-2024 | Yupelri |
| La Jolla Pharmaceutical Company | $21.87 | 2024 | Giapreza |
| Novartis Pharmaceuticals Corporation | $17.68 | 2023 | |
| Covis Pharma Gmbh | $15.09 | 2022 | |
| Shire North American Group INC | $12.86 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Devnani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.